Bellevue Asset Management / Bellevue Asset Management creates independent Advisory Board
processed and transmitted by Hugin AS. The issuer is solely responsible for the content
of this announcement.
PRESS RELEASE
Küsnacht, June 14, 2010
Investment expertise in healthcare sector strengthened
As part of the systematic expansion of its sector and investing expertise, Bellevue
Asset Management has created a Healthcare Advisory Board composed of highly qualified
executives with many years of experience as well as distinguished scientists. This
further strengthens the company’s proven competency in the healthcare sector as well as
its already extensive international network. The objectives here are detecting mega
trends and investment opportunities at a very early stage, systematically identifying
groundbreaking innovations and realistically evaluating their prospects of success and,
ultimately, using this knowledge to make sound and successful investment decisions.
The creation of an independent Healthcare Advisory Board marks another step forward in
the steadfast implementation of Bellevue Asset Management’s strategic expansion of its
asset management business. The company has attracted prominent executives and experts
with excellent credentials and track records to its international Advisory Board. They
are industry representatives with high R&D competence and who are very familiar with
regulatory processes or have decades of experience in managing international companies.
The newly constituted board chaired by William M. Burns, former CEO of the Pharma
Division at Roche, will focus its attention on trends and investment opportunities in
the healthcare sector.
The board members, internationally recognized experts representing diverse industrial
and academic backgrounds, will advise the investment specialists at Bellevue Asset
Management and support them in the evaluation of consequential medical and technical
innovations in the biotechnology and medical technology sectors as well as in other
areas, including the corresponding investment possibilities.
“The innovative forces at work in the healthcare sector remain as strong as ever, which
makes the early detection of critical trends and an accurate assessment of the chances
of their successful commercial realization all the more important. We are looking
forward to a fruitful and rewarding interdisciplinary exchange of knowledge and ideas
with the portfolio managers,” says William M. Burns, Chairman of the Advisory Board.
Hans-Peter Diener, CEO of Bellevue Asset Management, adds: “We are honored to be able to
consult such high-caliber professionals while screening, evaluating and realizing
investment opportunities, for it is only through an active discourse with the best
experts worldwide that specialist knowledge and expertise can be maintained and
developed at internationally competitive levels. This, in turn, enables us to detect
future investment ideas early on and realistically assess their prospects.”
The Healthcare Advisory Board consists of the following experts:
William M. Burns (Chairman)
Board member of Roche Group; ex-CEO Roche Pharma; Board member of Chugai and member of
the Advisory Board of Genentech; Board member of Shire and Crucell
Prof. Dr. Dr. Uwe Bicker
Aventis Foundation trustee; Board member of Sanofi-Aventis; Vice Chairman of Epigenomics
AG; Professor at the Faculty of Clinical Medicine Mannheim, University of Heidelberg
Prof. Dr. Stefan Catsicas
Co-founder of the Tilocor Life Science biotechnology group; Former Professor at the
School of Medicine in Lausanne and Professor, Vice President and Research Director at
the Swiss Federal Institute of Technology (Lausanne)
Dr. Jürgen Schwiezer
Ex-CEO Roche Diagnostics
Prof. Dr. Thomas Szucs
Chairman of Helsana Group and BB Biotech AG; Director of the Institute of Pharmaceutical
Medicine at the University of Basel
Prof. Dr. Otmar D. Wiestler
Chairman of the Management Board and Scientific Director of the German Cancer Research
Center, Heidelberg
Bellevue Asset Management is one of the leading providers of investment management
services in the healthcare sector, specifically in medical technology and biotechnology.
14 experts in the fields of biochemistry, molecular biology, medicine and economics
manage approximately CHF 2.2 billion using specialized sector strategies in the
healthcare sector. With an average of 10 years of professional experience and a network
of contacts spanning the globe, they are a key factor for competitive and sustainable
investment success.
Based on its profound healthcare expertise Bellevue Asset Management offers a
comprehensive range of investment vehicles:
Traditional investment vehicles
BB Biotech AG (listed investment company)
BB Biotech (Lux) Fund
BB Medtech (Lux) Fund
BB Healthcare (Lux) Fund
Non-traditional investment vehicles
BB Bioventures
BB Biotech Ventures II – III
BB Alpha Health (long/short equity fund)
For further information:
Bellevue Asset Management AG, Seestrasse 16/P.O. Box, CH-8700 Küsnacht/Zurich
Thomas Egger, Tel. +41 (44) 267 67 09, teg@bellevue.ch mailto:teg@bellevue.ch
Images available here
http://www.bellevue.ch/cms/bellevue_asset_management/page3508.html
(http://www.bellevue.ch/cms/bellevue_asset_management/page3508.html
http://www.bellevue.ch/cms/bellevue_asset_management/page3508.html )
Bellevue Asset Management
Bellevue Asset Management is an independent and highly specialized asset management
boutique focused on managing equity portfolios for selective sector and regional
strategies as well as institutional portfolios, particularly in the areas of healthcare,
new markets and Swiss/European equities.
HUG#1423774
Press Release Bellevue Asset Mgt (PDF) http://hugin.info/142988/R/1423774/372552.pdf
— End of Message —
Bellevue Asset Management
Seestrasse 16 / P.O. Box Kusnacht/Zurich Switzerland